Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Disease 1

Interventions

Blood Specimen Collection 6pembrolizumab 2fluciclovine F-18 2Surveys and Questionnaires 2Preoperative Exercise 2Magnetic Resonance Imaging 2Exercise 2Cryosurgery 2Bevacizumab 2tislelizumab 1neratinib 1imetelstat 1daratumumab 1atezolizumab 1abiraterone 1Waiting Lists 1Videotape Recording 1Urine Specimen Collection 1Triamcinolone Acetonide 1Transcutaneous Electric Nerve Stimulation 1Tomography, X-Ray Computed 1Thoracic Surgical Procedures 1TIC10 compound 1Sulfonylurea Compounds 1Standard of Care 1Specimen Handling 1Sodium-Glucose Transporter 2 Inhibitors 1Serologic Tests 1Sequence Analysis, RNA 1S-Adenosylmethionine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease × Food × 1 year × Clear all
NCT07299292 2025-12-23

Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)

SMED Clinical Research

Phase 2 Recruiting
60 enrolled
Genitourinary

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡